Clinical trials: sponsored by Henan Cancer Hospital
NSCLC, Brain Metastases
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Conditions
- NSCLC, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT04778800
- Testing
- almonertinib, LM-first line treatment, LM-second line treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04063683
- Testing
- Anlotinib Hydrochloride, Paclitaxel, cisplatin
- Where
- 6 sites in China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Gastric and Esophagogastric Junction Adenocarcinoma
PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma
This is a prospective single arm phase II clinical study to compare the safety and efficacy of PD-1monoclonal antibody +FLOT in patients with gastric adenocarcinoma/esophagus-gastric junction adenocarcinoma.
- Trial name
- NCT04341857
- Testing
- PD-1 Monoclonal Antibody(Sintilimab)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
Digestive System Tumors
A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
This is a prospective, open, phase I clinical study to evaluate the safety and tolerability of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system tumors
- Trial name
- NCT04615312
- Testing
- a CDK4 / 6 inhibitor and a MEK inhibitor
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Esophageal Neoplasms
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib is the first-line treatment of advanced esophageal squamous cell carcinoma.
- Trial name
- NCT05013697
- Testing
- Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib, Paclitaxel + Cisplatin + TQB2450 injection
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Advanced Gastric Carcinoma
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.
- Trial name
- NCT04948125
- Testing
- camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Central Nervous System Lymphoma
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
In view of the synergistic effects of rituximab, zanubrutinib, and lenalidomide and severe complications caused by current standard chemotherapy regimens in Patients for primary or secondary CNS lymphoma, we intend to conduct a…
- Trial name
- NCT04938297
- Testing
- Rituximab, Lenalidomide, Zanubrutinib, Lenalidomide, Zanubrutinib, Lenalidomide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Henan Cancer Hospital
Lung Adenocarcinoma
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
This is a prospective, randomized, open, multicenter phase Ⅱ study to evaluate the efficacy of cytokine-induced killer cells combined chemotherapy in stage Ⅳ naive EGFR wild-type lung adenocarcinoma.
- Trial name
- NCT02621333
- Testing
- CIK, chemotherapy
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer
Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer
The aim of this study was to evaluate the efficacy and safety of continuing cetuximab combined with chemotherapy after first-line progression in wild-type KRAS,NRAS and BRAF colorectal cancer.
- Trial name
- NCT04718038
- Testing
- Cetuximab combind mFOLFOX6/FOLFIRI
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
The multicenter real-world and propensity score matching comparative study was designed to explore the toxicity and effectiveness of Lobaplation or Cisplatin based adjuvant chemotherapy in esophageal carcinoma
- Trial name
- NCT03413436
- Testing
- Lobaplatin, Cisplatin
- Where
- China
- Volunteers
- 733 people
- Sponsor
- Henan Cancer Hospital
Advanced NSCLC With EGFR Mutation
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus gefitinib versus gefitinib monotherapy
- Trial name
- NCT03457337
- Testing
- S-1 plus Gefitinib, Gefitinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
The purpose of this study is to confirm the safety and efficacy of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer.
- Trial name
- NCT03389087
- Testing
- Apatinib and Etoposide Capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Lung Adenocarcinoma
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
This is a prospective, open, single-center, phase Ⅱ study to assess the efficacy and safety of alternating Icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR mutation.
- Trial name
- NCT02737774
- Testing
- Icotinib, Pemetrexed/Carboplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Tumor, Chemotherapy-induced Nausea and Vomiting
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
To compare the efficacy and safety of megestrol acetate dispersible tablets combined with 5-HT3 receptor antagonist and dexamethasone triple antiemetic regimen and 5-HT3 receptor antagonist and dexamethasone combined antiemetic…
- Trial name
- NCT04430361
- Testing
- Megestrol, 5-HT3 receptor antagonist, dexamethasone
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer, Extensive Disease
Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
Small cell lung cancer is a highly aggressive malignancy. Currently, there is no effective regimen for patients after the progression offirst-line chemotherapy.
- Conditions
- Small Cell Lung Cancer, Extensive Disease, Adoptive Cellular Immunotherapy, Chemotherapy
- Trial name
- NCT03983759
- Testing
- sintilimab maintenance
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Advanced Solid Tumor
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy
- Trial name
- NCT04268108
- Testing
- liquid tumor infiltrating lymphocytes
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Gastric Cancer
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .
- Trial name
- NCT03478943
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Henan Cancer Hospital
Gastric Carcinoma
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.
- Trial name
- NCT03735511
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Henan Cancer Hospital
Colorectal Cancer
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
The purpose of this study is to confirm the safety and efficacy of Apatinib plus S-1 as the Therapy of Advanced Colorectal Cancer.
- Trial name
- NCT03397199
- Testing
- Apatinib + S-1
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Henan Cancer Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
In recent years, with the progress in the treatment field, Non-Small Cell Lung Cancer(NSCLC) has become the most successful cancer species in precision medicine.
- Trial name
- NCT03790228
- Testing
- Anlotinib Combined With Pemetrexed And Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Henan Cancer Hospital